Literature DB >> 24590131

Melanoma: smart therapeutic strategies in immuno-oncology.

Alexander M M Eggermont1, Caroline Robert2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590131     DOI: 10.1038/nrclinonc.2014.36

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors:  Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

4.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

5.  Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alexander M M Eggermont
Journal:  Eur J Cancer       Date:  2013-07-29       Impact factor: 9.162

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

  9 in total
  12 in total

1.  Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities.

Authors:  Matshawandile Tukulula; Rose Hayeshi; Pascaline Fonteh; Debra Meyer; Abongile Ndamase; Michael T Madziva; Vincent Khumalo; Philip Labuschagne; Philip Lubuschagne; Brendon Naicker; Hulda Swai; Admire Dube
Journal:  Pharm Res       Date:  2015-02-28       Impact factor: 4.200

2.  Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation.

Authors:  Xueqing Hu; Fangzhen Jiang; Qi Bao; Huan Qian; Quan Fang; Zheren Shao
Journal:  Tumour Biol       Date:  2015-08-14

3.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 4.  Clinical cancer research: the past, present and the future.

Authors:  Vincent T DeVita; Alexander M M Eggermont; Samuel Hellman; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2014-09-23       Impact factor: 66.675

Review 5.  Prioritizing therapeutic targets using patient-derived xenograft models.

Authors:  K A Lodhia; A M Hadley; P Haluska; C L Scott
Journal:  Biochim Biophys Acta       Date:  2015-03-14

Review 6.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 7.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 8.  Combinatorial strategies for the induction of immunogenic cell death.

Authors:  Lucillia Bezu; Ligia C Gomes-de-Silva; Heleen Dewitte; Karine Breckpot; Jitka Fucikova; Radek Spisek; Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal:  Front Immunol       Date:  2015-04-24       Impact factor: 7.561

9.  Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells.

Authors:  Fangzhen Jiang; Kai Jin; Shenyu Huang; Qi Bao; Zheren Shao; Xueqing Hu; Juan Ye
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

10.  RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling.

Authors:  Guobiao Fan; Dan Ye; Songcheng Zhu; Jiajie Xi; Xudong Guo; Jing Qiao; Yukang Wu; Wenwen Jia; Guiying Wang; Guohuang Fan; Jiuhong Kang
Journal:  Oncotarget       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.